SAGIMET Aktie

>SAGIMET Aktienkurs

4.6 EUR (TradegateBSX)

Ask: 4.64 EUR / 1300 Stück

Bid: 4.56 EUR / 1800 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

SAGIMET Aktie über LYNX handeln

Intraday

1 Jahr

>SAGIMET Performance

1 Woche: +8,0%

1 Monat: -3,8%

3 Monate: -7,6%

6 Monate: -25,2%

1 Jahr: +117,0%

laufendes Jahr: -9,8%

>SAGIMET Aktie

Name:

SAGIMET BIOSCIENCES

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US7867001049 / A3CPAM

Symbol/ Ticker:

0O2 (Frankfurt) / SGMT (NASDAQ)

Kürzel:

FRA:0O2, ETR:0O2, 0O2:GR, NASDAQ:SGMT

Index:

Webseite:

https://www.sagimet.com/

Profil:

Sagimet Biosciences Inc. is a biotechnology company focused on the development of therapeutics targeting critical metabolic pathways in fibrotic diseases and cancer. The company's primary function is to leverage its proprietary platform to discover a..
>Volltext..

Marktkapitalisierung:

145.34 Mio. EUR

Unternehmenswert:

49.14 Mio. EUR

Umsatz:

EBITDA:

-49.28 Mio. EUR

Nettogewinn:

-44.21 Mio. EUR

Gewinn je Aktie:

-1.37 EUR

Schulden:

0.07 Mio. EUR

Liquide Mittel:

30.34 Mio. EUR

Operativer Cashflow:

-39.55 Mio. EUR

Bargeldquote:

22.18

Umsatzwachstum:

Gewinnwachstum:

1.28%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

SAGIMET

Letzte Datenerhebung:

04.04.26

>SAGIMET Kennzahlen

Aktien/ Unternehmen:

Aktien: 32.02 Mio. St.

Frei handelbar: 84.12%

Leerverk. Aktien: 11.88%

Rückkaufquote: -0.16%

Mitarbeiter: 16

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 466.94%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 1.41

PEG-Ratio: -0.32

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -36.89%

Eigenkaprendite: -38.2%

>SAGIMET Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung

>SAGIMET Chart & Kurs - NASDAQ

>SAGIMET News

11.03.26 - 20:42	Sagimet Biosciences GAAP EPS of -$0.29 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.03.26 - 12:33	Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates (GlobeNewswire EN)
	Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination...

25.02.26 - 13:03	Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences (GlobeNewswire EN)
	SAN MATEO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in three upcoming investor conferences....

13.02.26 - 01:01	Insiderhandel: President & CEO verkauft Aktien von Sagimet Biosciences im Wert von 64865 USD (Insiderkauf)
	Happel, David - Vorstand - Tag der Transaktion: 2026-02-10...

13.02.26 - 01:01	Insiderhandel: Chief Financial Officer verkauft Aktien von Sagimet Biosciences im Wert von 7033 USD (Insiderkauf)
	Chauche, Thierry - Vorstand - Tag der Transaktion: 2026-02-10...

13.02.26 - 01:01	Insiderhandel: Chief Medical Officer verkauft Aktien von Sagimet Biosciences im Wert von 19511 USD (Insiderkauf)
	Martins, Eduardo Bruno - Vorstand - Tag der Transaktion: 2026-02-10...

13.02.26 - 01:01	Insiderhandel: Chief Legal & Admin. Officer verkauft Aktien von Sagimet Biosciences im Wert von 14054 USD (Insiderkauf)
	Rozek, Elizabeth - Vorstand - Tag der Transaktion: 2026-02-10...

05.02.26 - 13:03	Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences (GlobeNewswire EN)
	SAN MATEO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences....

03.02.26 - 17:03	Sagimet a new buy at Guggenheim on promise of MASH, acne asset (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

02.02.26 - 18:24	Sagimet-Aktie legt nach positiven Phase-3-Sicherheitsdaten für Akne-Wirkstoff zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

02.02.26 - 13:03

Sagimet Announces Positive 52-Week Data from License Partner Ascletis′ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne (GlobeNewswire EN)

SAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis Pharma Inc. issued a press release on January 29th reporting positive topline results in the open-label Phase 3 trial evaluating the long-term safety of ASC40 (denifanstat) tablets in patients with moderate to severe acne. Denifanstat is a once-daily oral small molecule fatty acid synthase (FASN) inhibitor being developed by Ascletis as ASC40 for acne in China and by Sagimet for MASH in the rest of the world. Sagimet has granted an exclusive license to denifanstat for China to Ascletis Bioscience Co. Ltd. (Ascletis), of which Ascletis Pharma Inc. is the parent company....

29.01.26 - 14:21	Sagimet down as Chinese partner posts late-stage trial data for acne therapy (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.01.26 - 13:03

Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference (GlobeNewswire EN)

SAN MATEO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that it will be presenting a poster at the upcoming 10th Annual MASH-TAG Conference being held January 8-10, 2026 in Park City, Utah. The poster will focus on the observed anti-fibrotic effects in F3 and qFibrosis stage 4 MASH patients in the Phase 2b FASCINATE-2 clinical trial of fatty acid synthase (FASN) inhibitor denifanstat....

18.12.25 - 13:03

Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination (GlobeNewswire EN)

SAN MATEO, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced positive results in the Phase 1 pharmacokinetic (PK) trial of a combination of its oral once-daily fatty acid synthase (FASN) inhibitor, denifanstat, and a thyroid hormone receptor beta (THR-β) agonist, resmetirom....

17.12.25 - 19:09	Sagimet rises as licensing deal with Teva unit targets Madrigal drug (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

17.12.25 - 13:06

Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet′s Fixed Dose Combination Program (GlobeNewswire EN)

SAN MATEO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways for metabolic and fibrotic diseases, today announced entry into a license agreement with Assia Chemical Industries Ltd. (Assia), doing business as TAPI Technology & API Services (TAPI), a subsidiary of Teva Pharmaceutical Industries Ltd....

10.12.25 - 13:06

Sagimet′s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China′s National Medical Products Administration (GlobeNewswire EN)

SAN MATEO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis Pharma Inc. issued a December 10 statement that China's National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for denifanstat for the treatment of moderate to severe acne. Sagimet has granted an exclusive license to denifanstat for China to Ascletis Bioscience Co. Ltd. (Ascletis), of which Ascletis Pharma Inc. is the parent company....

09.12.25 - 22:06

Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)

SAN MATEO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that, in connection with the hiring of three employees, the Compensation Committee of Sagimet's Board of Directors approved inducement grants of 42,800 stock options in aggregate to purchase shares of the Company's Series A common stock as determined based on the Black Scholes value on December 9, 2025, to be granted on December 9, 2025 to the three newly-hired employees....

22.11.25 - 03:01	Insiderhandel: Executive Chairman verkauft Aktien von Sagimet Biosciences im Wert von 289979 USD (Insiderkauf)
	Kemble, George - Vorstand - Tag der Transaktion: 2025-11-20...

20.11.25 - 13:03

Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference (GlobeNewswire EN)

SAN MATEO, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the 8th Annual Evercore ISI Healthcare Conference on Tuesday, December 2, 2025, in Coral Gables, Florida, with a fireside chat at 12:55pm ET (link here)....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram